Semaglutide 7.2 mg

Wegovy HD · Novo Nordisk. A triple-strength dose of Wegovy. More weight loss than the 2.4 mg dose, but altered skin sensations were reported by about 1 in 5 people.

Average weight loss

20.7%

Stopped for side effects

n/r

Trial length

72 wk

Ranking score

n/r

STEP UP results

Phase 3 · 72 weeks · 7.2 mg weekly
Adults with obesity, no diabetes

Weight loss

20.7%

Nausea

n/r

Vomiting

n/r

Diarrhea

n/r

Constipation

n/r

Quit due to side effects

n/r

n/r = not reported. Counting everyone who started, weight loss was 18.7%. Skin-sensation events (dysesthesia): 22%.

Worth knowing

Skin-sensation events (dysesthesia and related terms): 22% vs 6% on 2.4 mg and 0.3% on placebo.
Individual stomach side-effect rates not yet published in a form we can verify, so it is not scored.

–

Not yet ranked

Side-effect data incomplete. We rank only drugs with a completed Phase 3 trial and published side-effect rates.

At a glance

Company: Novo Nordisk
Targets: GLP-1
Molecule: Peptide
Dosing: Injection, weekly
Status: FDA approved (Mar 19, 2026)

Compare with another drug

Sources

FDA approves Wegovy HD, HCPLive, Mar 2026

History

Mar 19, 2026
FDA approves Wegovy HD (semaglutide 7.2 mg).